全文获取类型
收费全文 | 4788篇 |
免费 | 404篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 185篇 |
妇产科学 | 83篇 |
基础医学 | 515篇 |
口腔科学 | 59篇 |
临床医学 | 575篇 |
内科学 | 957篇 |
皮肤病学 | 61篇 |
神经病学 | 674篇 |
特种医学 | 115篇 |
外科学 | 435篇 |
综合类 | 39篇 |
一般理论 | 11篇 |
预防医学 | 654篇 |
眼科学 | 154篇 |
药学 | 256篇 |
中国医学 | 5篇 |
肿瘤学 | 379篇 |
出版年
2024年 | 12篇 |
2023年 | 62篇 |
2022年 | 75篇 |
2021年 | 178篇 |
2020年 | 118篇 |
2019年 | 161篇 |
2018年 | 190篇 |
2017年 | 138篇 |
2016年 | 127篇 |
2015年 | 138篇 |
2014年 | 156篇 |
2013年 | 259篇 |
2012年 | 321篇 |
2011年 | 347篇 |
2010年 | 188篇 |
2009年 | 159篇 |
2008年 | 261篇 |
2007年 | 324篇 |
2006年 | 274篇 |
2005年 | 258篇 |
2004年 | 234篇 |
2003年 | 201篇 |
2002年 | 187篇 |
2001年 | 59篇 |
2000年 | 60篇 |
1999年 | 55篇 |
1998年 | 31篇 |
1997年 | 27篇 |
1996年 | 19篇 |
1995年 | 21篇 |
1994年 | 13篇 |
1993年 | 17篇 |
1992年 | 34篇 |
1991年 | 76篇 |
1990年 | 52篇 |
1989年 | 48篇 |
1988年 | 36篇 |
1987年 | 37篇 |
1986年 | 43篇 |
1985年 | 49篇 |
1984年 | 37篇 |
1983年 | 14篇 |
1982年 | 10篇 |
1980年 | 6篇 |
1979年 | 12篇 |
1978年 | 6篇 |
1977年 | 9篇 |
1976年 | 10篇 |
1972年 | 6篇 |
1971年 | 9篇 |
排序方式: 共有5203条查询结果,搜索用时 15 毫秒
51.
Tanya M Tekautz Christine E Fuller Susan Blaney Maryam Fouladi Alberto Broniscer Thomas E Merchant Matthew Krasin James Dalton Gregory Hale Larry E Kun Dana Wallace Richard J Gilbertson Amar Gajjar 《Journal of clinical oncology》2005,23(7):1491-1499
PURPOSE: To describe clinical features, therapeutic approaches, and prognostic factors in pediatric patients with atypical teratoid/rhabdoid tumors (ATRT) treated at St Jude Children's Research Hospital (SJCRH). PATIENTS AND METHODS: Primary tumor samples from patients diagnosed with ATRT at SJCRH between July 1984 and June 2003 were identified. Pathology review included histologic, immunohistochemical analysis, and fluorescence in situ hybridization for SMARCB1 (also known as hSNF5/INI1) deletion. Clinical records of patients with pathologic confirmation of ATRT were reviewed. RESULTS: Thirty-seven patients were diagnosed with ATRT at SJCRH during the 19-year study interval. Six patients were excluded from this clinical review based on pathologic or clinical criteria. Of the remaining 31 patients, 22 were younger than 3 years. Posterior fossa primary lesions and metastatic disease at diagnosis were more common in younger patients with ATRT. All patients underwent surgical resection; 30 received subsequent chemotherapy. The majority of patients aged 3 years or older received postoperative craniospinal radiation. Two-year event-free (EFS) and overall survival (OS) of children aged 3 years or older (EFS, 78% + 14%; OS, 89% +/- 11%) were significantly better than those for younger patients (EFS, 11% +/- 6%; OS, 17% +/- 8%); EFS, P = .009 and OS, P = .0001. No other clinical characteristics were predictive of survival. Three of four patients 3 years or older with progressive disease were successfully rescued with ifosfamide, carboplatin, and etoposide therapy. CONCLUSION: Children presenting with ATRT before the age of 3 years have a dismal prognosis. ATRT presenting in older patients can be cured using a combination of radiation and high-dose alkylating therapy. Older patients with relapsed ATRT can have salvage treatment using ICE chemotherapy. 相似文献
52.
53.
Brian Weiss Brigitte C. Widemann Pamela Wolters Eva Dombi Alexander Vinks Alan Cantor John Perentesis Elizabeth Schorry Nicole Ullrich David H. Gutmann James Tonsgard David Viskochil Bruce Korf Roger J. Packer Michael J. Fisher 《Neuro-oncology》2015,17(4):596-603
BackgroundPlexiform neurofibromas (PNs) are benign peripheral nerve sheath tumors that arise in one-third of individuals with neurofibromatosis type 1 (NF1). They may cause significant disfigurement, compression of vital structures, neurologic dysfunction, and/or pain. Currently, the only effective management strategy is surgical resection. Converging evidence has demonstrated that the NF1 tumor suppressor protein, neurofibromin, negatively regulates activity in the mammalian Target of Rapamycin pathway.MethodsWe employed a 2-strata clinical trial design. Stratum 1 included subjects with inoperable, NF1-associated progressive PN and sought to determine whether sirolimus safely and tolerably increases time to progression (TTP). Volumetric MRI analysis conducted at regular intervals was used to determine TTP relative to baseline imaging.ResultsThe estimated median TTP of subjects receiving sirolimus was 15.4 months (95% CI:14.3–23.7 mo), which was significantly longer than 11.9 months (P < .001), the median TTP of the placebo arm of a previous PN clinical trial with similar eligibility criteria.ConclusionsThis study demonstrated that sirolimus prolongs TTP by almost 4 months in patients with NF1-associated progressive PN. Although the improvement in TTP is modest, given the lack of significant or frequent toxicity and the availability of few other treatment options, the use of sirolimus to slow the growth of progressive PN could be considered in select patients. 相似文献
54.
Tjede Funk Francesco Innocenti Joana Gomes Dias Lina Nerlander Tanya Melillo Charmaine Gauci Jackie M Melillo Patrik Lenz Helena Sebestova Pavel Slezak Iva Vlckova Jacob Dag Berild Camilla Mauroy Elina Seppl Ragnhild Tnnessen Anne Vergison Joël Mossong Silvana Masi Laetitia Huiart Gillian Cullen Niamh Murphy Lois OConnor Joan ODonnell Piers Mook Richard G Pebody Nick Bundle 《Euro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin》2022,27(35)
BackgroundUnderlying conditions are risk factors for severe COVID-19 outcomes but evidence is limited about how risks differ with age.AimWe sought to estimate age-specific associations between underlying conditions and hospitalisation, death and in-hospital death among COVID-19 cases.MethodsWe analysed case-based COVID-19 data submitted to The European Surveillance System between 2 June and 13 December 2020 by nine European countries. Eleven underlying conditions among cases with only one condition and the number of underlying conditions among multimorbid cases were used as exposures. Adjusted odds ratios (aOR) were estimated using 39 different age-adjusted and age-interaction multivariable logistic regression models, with marginal means from the latter used to estimate probabilities of severe outcome for each condition–age group combination.ResultsCancer, cardiac disorder, diabetes, immunodeficiency, kidney, liver and lung disease, neurological disorders and obesity were associated with elevated risk (aOR: 1.5–5.6) of hospitalisation and death, after controlling for age, sex, reporting period and country. As age increased, age-specific aOR were lower and predicted probabilities higher. However, for some conditions, predicted probabilities were at least as high in younger individuals with the condition as in older cases without it. In multimorbid patients, the aOR for severe disease increased with number of conditions for all outcomes and in all age groups.ConclusionWhile supporting age-based vaccine roll-out, our findings could inform a more nuanced, age- and condition-specific approach to vaccine prioritisation. This is relevant as countries consider vaccination of younger people, boosters and dosing intervals in response to vaccine escape variants. 相似文献
55.
Niven Mehra Karim Fizazi Johann S de Bono Philippe Barthlmy Tanya Dorff Adam Stirling Jean-Pascal Machiels Davide Bimbatti Deepak Kilari Herlinde Dumez Consuelo Buttigliero Inge M van Oort Elena Castro Hsiang-Chun Chen Nicola Di Santo Liza DeAnnuntis Cynthia G Healy Giorgio V Scagliotti 《The oncologist》2022,27(10):e783
BackgroundThe phase II TALAPRO-1 study () demonstrated durable antitumor activity in men with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). Here, we detail the safety profile of talazoparib.Patients and MethodsMen received talazoparib 1 mg/day (moderate renal impairment 0.75 mg/day) orally until radiographic progression, unacceptable toxicity, investigator decision, consent withdrawal, or death. Adverse events (AEs) were evaluated: incidence, severity, timing, duration, potential overlap of selected AEs, dose modifications/discontinuations due to AEs, and new clinically significant changes in laboratory values and vital signs.ResultsIn the safety population (N = 127; median age 69.0 years), 95.3% (121/127) experienced all-cause treatment-emergent adverse events (TEAEs). Most common were anemia (48.8% [62/127]), nausea (33.1% [42/127]), decreased appetite (28.3% [36/127]), and asthenia (23.6% [30/127]). Nonhematologic TEAEs were generally grades 1 and 2. No grade 5 TEAEs or deaths were treatment-related. Hematologic TEAEs typically occurred during the first 4-5 months of treatment. The median duration of grade 3-4 anemia, neutropenia, and thrombocytopenia was limited to 7-12 days. No grade 4 events of anemia or neutropenia occurred. Neither BRCA status nor alteration origin significantly impacted the safety profile. The median (range) treatment duration was 6.1 (0.4-24.9) months; treatment duration did not impact the incidence of anemia. Only 3 of the 15 (11.8% [15/127]) permanent treatment discontinuations were due to hematologic TEAEs (thrombocytopenia 1.6% [2/127]; leukopenia 0.8% [1/127]).ConclusionCommon TEAEs associated with talazoparib could be managed through dose modifications/supportive care. Demonstrated efficacy and a manageable safety profile support continued evaluation of talazoparib in mCRPC.ClinicalTrials.gov identifier NCT03148795 NCT03148795相似文献
56.
Iodine-125 radiation of posterior uveal melanoma 总被引:1,自引:0,他引:1
S Packer 《Ophthalmology》1987,94(12):1621-1626
Twenty-eight cases of posterior choroidal melanoma were treated with iodine-125 in gold eye plaques. Eleven cases were located within 3.0 mm of the optic nerve (group A), nine were within 3.0 mm of the fovea (group B), and eight were within 3.0 mm of the optic nerve and fovea (group C). The mean follow-up of group A was 46.3 months; group B, 25.5 months; and group C, 42.7 months. Complications included macular edema, cataract and tumor growth. Visual acuity remained within two lines of that tested preoperatively for 4 of 11 patients in group A, 4 of 9 in group B, and 5 of 8 in group C. These results with iodine-125 suggest it as an appropriate treatment for patients with choroidal melanoma located near optic nerve and/or macula. 相似文献
57.
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03)
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
58.
J. Justin Ebenezer Sargunaraj Joby Elizabeth Ninan Rashmi Tanya Boaz Nithya Sara Mani Rajat Basak Ranjeetha Rachel Inja Rita Ruby A. Albert Suma Susan Mathews 《Indian journal of otolaryngology and head and neck surgery》2023,75(2):322
Objective To study the outcomes in terms of airway, voice and swallowing as well as the economic impact of the trauma on patients’ finances and the constrained health infrastructure due to the pandemic. Materials and methods Study design Retrospective study. Setting: Tertiary care teaching hospital. Subjects and methods: A retrospective study was done of the 19 subjects who sustained acute laryngotracheal trauma during the SARS CoV-2 pandemic and was managed at our institution from January 2020 to September 2021.Results Change in voice was the most common presenting symptom and thyroid cartilage fractures were the commonest cartilage injury noted. It was found that 93% (decannulated) of the patients had good functional outcome and 90% of them required financial support to meet the medical expenses.Conclusion During the COVID 19 pandemic, it was not only, early presentation, timely detection and intervention by the treating team, but also the multidisciplinary teamwork and the support system that facilitated the recuperation and restoration of these traumatized individuals back into society with good laryngeal function. 相似文献
59.